Fizzah Ikram Ul Haq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fizzah Ikram Ul Haq has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aaitain Ikram Ul Haq
University of the Punjab
1 shared publication - Alaa Eldeeb
Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication - Alyaa Ahmed Ibrahim
Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication Amr Ibrahim
Faculty of Medicine, Monoufia University, Monoufia, Egypt
1 shared publication- Archi Mehta
GMERS Medical College, Gotri, Vadodara, Gujarat, India
1 shared publication - Bhawan Kumar
Department of Internal Medicine, Dow University of Health Sciences, Karachi 75600, Pakistan
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1) , 886
Infant mortality related to congenital heart disease in the United States, 1999–2025: trends, disparities, and projections to 2040
Introduction: Congenital heart disease remains a leading congenital cause of infant mortality in the United States despite major advances in diagnosis and neonatal care. This study evaluated national mortality trends from 1999 to 2025, examined sex and racial disparities, and projected future burden through 2040 using time-series forecasting. Methods: A retrospective CDC WONDER analysis examined U.S. infant (< 1 year) CHD mortality from 1999 to 2025 using ICD-10 codes Q20–Q26. Deaths listing CHD as underlying or contributing cause were included. Crude mortality rates (CMRs) per 100,000 with 95% CIs were calculated. Trends were evaluated using Joinpoint regression analysis to estimate annual percent change (APC) and average annual percent change (AAPC). Forecasts to 2040 used ARIMA and ETS models, stratified by sex and race/ethnicity. Results: From 1999 to 2025, 55,719 infant deaths related to CHD were recorded in the United States, 92.16% in medical facilities. The CMRs declined from 69.66 in 1999 to 46.44 in 2025 (AAPC − 1.32%) and is projected at 37.51 by 2040. Male mortality remained higher than female (54.86 vs. 52.04). NH Black infants had the highest mean mortality (71.87), while NH Asian/Pacific Islander infants showed the steepest decline (AAPC − 2.30%). Recent increases appeared in NH White infants after 2018 (APC 1.56%) and Hispanic infants after 2020 (APC 3.48%) overall. Conclusion: Infant CHD related mortality declined substantially from 1999 to 2025 and is projected to continue decreasing through 2040; however, persistent excess mortality in male, NH Black, and Hispanic infants underscores enduring demographic disparities in outcomes.
- 12 November 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1) , 886
Open AccessInfant mortality related to congenital heart disease in the United States, 1999–2025: trends, disparities, and projections to 2040
Introduction: Congenital heart disease remains a leading congenital cause of infant mortality in the United States despite major advances in diagnosis and neonatal care. This study evaluated national mortality trends from 1999 to 2025, examined sex and racial disparities, and projected future burden through 2040 using time-series forecasting. Methods: A retrospective CDC WONDER analysis examined U.S. infant (< 1 year) CHD mortality from 1999 to 2025 using ICD-10 codes Q20–Q26. Deaths listing CHD as underlying or contributing cause were included. Crude mortality rates (CMRs) per 100,000 with 95% CIs were calculated. Trends were evaluated using Joinpoint regression analysis to estimate annual percent change (APC) and average annual percent change (AAPC). Forecasts to 2040 used ARIMA and ETS models, stratified by sex and race/ethnicity. Results: From 1999 to 2025, 55,719 infant deaths related to CHD were recorded in the United States, 92.16% in medical facilities. The CMRs declined from 69.66 in 1999 to 46.44 in 2025 (AAPC − 1.32%) and is projected at 37.51 by 2040. Male mortality remained higher than female (54.86 vs. 52.04). NH Black infants had the highest mean mortality (71.87), while NH Asian/Pacific Islander infants showed the steepest decline (AAPC − 2.30%). Recent increases appeared in NH White infants after 2018 (APC 1.56%) and Hispanic infants after 2020 (APC 3.48%) overall. Conclusion: Infant CHD related mortality declined substantially from 1999 to 2025 and is projected to continue decreasing through 2040; however, persistent excess mortality in male, NH Black, and Hispanic infants underscores enduring demographic disparities in outcomes.
- Open Access
- 13 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6258
Mortality Trends Involving Cardiac Arrest and Fluid, Electrolyte, and Acid–Base Disorders in U.S. Adults, 2004–2024
Background/Objectives: Cardiac arrest and fluid, electrolyte, and acid–base disorders frequently coexist in critically ill patients and are associated with poor clinical outcomes. However, long-term population-level trends in mortality involving both conditions remain poorly characterized. This study evaluated temporal trends and demographic disparities in mortality involving cardiac arrest and fluid, electrolyte, and acid–base disorders among U.S. adults from 2004 to 2024. Methods: We conducted a retrospective population-based study using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Adults aged ≥25 years with cardiac arrest (ICD-10: I46) and fluid, electrolyte, and acid–base disorders (ICD-10: E87) listed anywhere on the same death certificate between 2004 and 2024 were included. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by demographic and geographic characteristics. Results: A total of 152,937 deaths involved both cardiac arrest and fluid, electrolyte, and acid–base disorders during the study period. The AAMR nearly doubled, increasing from 2.06 (95% CI, 2.00–2.13) in 2004 to 4.08 (95% CI, 4.00–4.16) in 2024, corresponding to an overall AAPC of 3.42% (95% CI, 2.58–4.26; p < 0.001). Mortality remained consistently higher among males, adults aged ≥65 years, and non-Hispanic Black individuals, with significant increases observed across all demographic groups. The West demonstrated the highest regional mortality burden (AAPC, 3.75%; p < 0.001). Urbanization analyses (2004–2020) showed higher mortality in non-metropolitan than metropolitan areas (AAPCs, 5.36% vs. 4.13%; both p < 0.001). Mortality increased through 2021 before declining modestly during 2021–2024. Conclusions: Mortality involving both cardiac arrest and fluid, electrolyte, and acid–base disorders increased substantially in the United States over the past two decades, with persistent disparities in age, sex, race/ethnicity, and geography. These findings identify populations at increased risk and support targeted public health strategies, equitable healthcare access, and improved recognition and management of metabolic disturbances in patients at risk for cardiac arrest.
- 13 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6258
Open AccessMortality Trends Involving Cardiac Arrest and Fluid, Electrolyte, and Acid–Base Disorders in U.S. Adults, 2004–2024
Background/Objectives: Cardiac arrest and fluid, electrolyte, and acid–base disorders frequently coexist in critically ill patients and are associated with poor clinical outcomes. However, long-term population-level trends in mortality involving both conditions remain poorly characterized. This study evaluated temporal trends and demographic disparities in mortality involving cardiac arrest and fluid, electrolyte, and acid–base disorders among U.S. adults from 2004 to 2024. Methods: We conducted a retrospective population-based study using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Adults aged ≥25 years with cardiac arrest (ICD-10: I46) and fluid, electrolyte, and acid–base disorders (ICD-10: E87) listed anywhere on the same death certificate between 2004 and 2024 were included. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by demographic and geographic characteristics. Results: A total of 152,937 deaths involved both cardiac arrest and fluid, electrolyte, and acid–base disorders during the study period. The AAMR nearly doubled, increasing from 2.06 (95% CI, 2.00–2.13) in 2004 to 4.08 (95% CI, 4.00–4.16) in 2024, corresponding to an overall AAPC of 3.42% (95% CI, 2.58–4.26; p < 0.001). Mortality remained consistently higher among males, adults aged ≥65 years, and non-Hispanic Black individuals, with significant increases observed across all demographic groups. The West demonstrated the highest regional mortality burden (AAPC, 3.75%; p < 0.001). Urbanization analyses (2004–2020) showed higher mortality in non-metropolitan than metropolitan areas (AAPCs, 5.36% vs. 4.13%; both p < 0.001). Mortality increased through 2021 before declining modestly during 2021–2024. Conclusions: Mortality involving both cardiac arrest and fluid, electrolyte, and acid–base disorders increased substantially in the United States over the past two decades, with persistent disparities in age, sex, race/ethnicity, and geography. These findings identify populations at increased risk and support targeted public health strategies, equitable healthcare access, and improved recognition and management of metabolic disturbances in patients at risk for cardiac arrest.
- Open Access
- 26 August 2025
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 75 (09) , 1511
Finerenone: a game changer for chronic kidney disease patients with type 2 diabetes
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance. According to the International Diabetes Federation (IDF), 1 in 10 people globally suffer from diabetes mellitus. The comparative adult prevalence rate of diabetes mellitus in Pakistan is estimated to be 30.8 % (1). One of the most prevalent complications of Type 2 Diabetes is chronic kidney disease (CKD). CKD is estimated to affect 50% of the population suffering from T2D (2). Traditionally, RAAS and SGLT-2 inhibitors are used as interventions to decline the progression of CKD. While effective, a novel therapeutic option, finerenone, has recently emerged as a breakthrough in improving both renal and cardiovascular outcomes in patients with CKD and T2D (3). Finerenone is a non-steroidal mineralocorticoid receptor antagonist that selectively inhibits aldosterone’s effects at its receptor. Unlike steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, finerenone offers significant renal protection without causing substantial elevations in serum potassium levels (4). Clinical trials have demonstrated that finerenone significantly reduces the urine albumin-to-creatinine ratio, slows estimated glomerular filtration rate (eGFR) decline, and mitigates progression to end-stage renal disease (5). Furthermore, finerenone does not cause significant rise in serum potassium levels which is a major side effect of steroidal mineralocorticoid receptor antagonists i.e. spironolactone and eplerenone. Thus, finerenone has almost the same effect along with a lower risk of hyperkalaemia as compared to that of steroidal mineralocorticoid receptor antagonists (4). Moreover, the lower risk of hyperkalaemia associated with finerenone makes it a safer alternative for long-term use. The drug’s beneficial effects in combination with RAAS and SGLT-2 inhibitors are now reflected in international treatment guidelines for CKD management in patients with T2D (3). With the recent availability of finerenone in Pakistan, it is the need of the hour to spread the word about this ground breaking drug and revise guidelines across urban and rural health care settings of Pakistan so that mortality and morbidity can be reduced amongst patients with CKD in T2D. Through these steps, the disease burden of end stage kidney failure amongst T2D patients in Pakistan can be reduced eventually.
- 26 August 2025
- Published by Pakistan Medical Association in Journal of the Pakistan Medical Association
- Vol. 75 (09) , 1511
Open AccessFinerenone: a game changer for chronic kidney disease patients with type 2 diabetes
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance. According to the International Diabetes Federation (IDF), 1 in 10 people globally suffer from diabetes mellitus. The comparative adult prevalence rate of diabetes mellitus in Pakistan is estimated to be 30.8 % (1). One of the most prevalent complications of Type 2 Diabetes is chronic kidney disease (CKD). CKD is estimated to affect 50% of the population suffering from T2D (2). Traditionally, RAAS and SGLT-2 inhibitors are used as interventions to decline the progression of CKD. While effective, a novel therapeutic option, finerenone, has recently emerged as a breakthrough in improving both renal and cardiovascular outcomes in patients with CKD and T2D (3). Finerenone is a non-steroidal mineralocorticoid receptor antagonist that selectively inhibits aldosterone’s effects at its receptor. Unlike steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, finerenone offers significant renal protection without causing substantial elevations in serum potassium levels (4). Clinical trials have demonstrated that finerenone significantly reduces the urine albumin-to-creatinine ratio, slows estimated glomerular filtration rate (eGFR) decline, and mitigates progression to end-stage renal disease (5). Furthermore, finerenone does not cause significant rise in serum potassium levels which is a major side effect of steroidal mineralocorticoid receptor antagonists i.e. spironolactone and eplerenone. Thus, finerenone has almost the same effect along with a lower risk of hyperkalaemia as compared to that of steroidal mineralocorticoid receptor antagonists (4). Moreover, the lower risk of hyperkalaemia associated with finerenone makes it a safer alternative for long-term use. The drug’s beneficial effects in combination with RAAS and SGLT-2 inhibitors are now reflected in international treatment guidelines for CKD management in patients with T2D (3). With the recent availability of finerenone in Pakistan, it is the need of the hour to spread the word about this ground breaking drug and revise guidelines across urban and rural health care settings of Pakistan so that mortality and morbidity can be reduced amongst patients with CKD in T2D. Through these steps, the disease burden of end stage kidney failure amongst T2D patients in Pakistan can be reduced eventually.